The Effect of Aromatherapy on the Insulin Injection Pain

February 22, 2021 updated by: Hatice Demirağ, Karadeniz Technical University

The Effect of Topically Administered Lavender Aromatherapy on the Pain of Insulin Injection in Diabetic Patients: A Double-Blind Randomized Controlled Clinical Trial

Needle phobia occurs in more than half of diabetic patients due to the pain caused by frequent insulin injection. Therefore, this study evaluated the effect of topically administered lavender aromatherapy on the pain of insulin injection in diabetic patients.

Study Overview

Detailed Description

Diabetes Mellitus (DM) is a serious chronic disease that negatively affects the quality of life. To control the course of the disease and to reduce its complications, insulin treatment is planned for the whole life of Type 1 diabetic patients, and frequently for approximately 40% of Type 2 diabetic patients. Frequent or incorrect administration of insulin injections may lead to the development of complications such as regional pain, ecchymosis, or hematoma on the injection site. It is emphasized that the pain caused by repeated insulin injections negatively affects the psychological well-being of the individuals as well as their physical comfort. Pain control is one of the main tasks of nurses. By alleviating pain, the patient's acceptance of treatment increases, and thus the quality of life improves. In the literature, lavender is reported to have the ability to heal burns and insect bites as well as analgesic, wound healing, antibacterial, antifungal, sedative, and antidepressant effects. The main components of lavender, such as lavender and linalyl acetate and linalool, are also recommended as topical analgesics in animal models. Whatever the cause, acute pain is a serious problem for individuals with chronic illnesses. Therefore, this study evaluated the effect of topically administered lavender aromatherapy on the pain of insulin injection in diabetic patients.

Study Type

Interventional

Enrollment (Actual)

180

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Trabzon, Turkey, 61800
        • Karadeniz Tecnical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • being 18 years of age or older,
  • having Type-1 DM or Type-2 DM disease,
  • being conscious and communicating, not having mental and cognitive impairment,
  • not having eczema and fragrance allergy to lavender,
  • not having an alcohol or narcotic addiction,
  • not having a head injury or convulsion history,
  • not having a diabetes-related neuropathy, and
  • if the patient took sedatives or analgesics, at least 6 hours would pass,

Exclusion Criteria:

  • having a history of addiction or diagnosed psychological disorders,
  • having an unstable hemodynamic status,
  • having skin disease symptoms such as wounds and eczema at the insulin injection site and,
  • having an allergy to lavender.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Topical lavender oil group
Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients.
PLACEBO_COMPARATOR: Placebo group
Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients. No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients.
NO_INTERVENTION: Control groups
Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured.No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Level before insulin injection
Time Frame: day 1
It was evaluated between the Verbal Category Scale (VCS) pain scores of the patients in the topical lavender oil group before insulin injection. Verbal Category Scale is based on the patient's choice of the most appropriate word to identify his/her pain. Accordingly, the patient was asked to rate his/her pain between 0-4 as 0; no pain, 1: mild pain, 2: severe pain, 3: very severe pain, 4: unbearable pain.
day 1
Pain Level before insulin injection
Time Frame: day 1
It was evaluated between the Visual Analogue Scale (VAS) pain scores of the patients in the topical lavender oil group before insulin injection. Visual Analogue Scale is used to digitalize the pain level that cannot be measured numerically. A line with a length of 100 mm has the words "no pain" at one end and "the most unbearable pain" on the other. The patient indicates his/her pain by choosing the most appropriate place on the line. Then, the level of pain experienced by the patient is determined by using a scale with scores between 0-10. According to this scoring system, less than 3 points indicate mild pain, 3-6 points indicate moderate pain, and more than 6 points indicate severe pain.
day 1
Pain Level after insulin injection
Time Frame: day 1
It was evaluated between the VCS pain scores of the patients in the topical lavender oil group during insulin injection. Verbal Category Scale is based on the patient's choice of the most appropriate word to identify his/her pain. Accordingly, the patient was asked to rate his/her pain between 0-4 as 0; no pain, 1: mild pain, 2: severe pain, 3: very severe pain, 4: unbearable pain.
day 1
Pain Level after insulin injection
Time Frame: day 1
It was evaluated between the VAS pain scores of the patients in the topical lavender oil group during insulin injection. Visual Analogue Scale is used to digitalize the pain level that cannot be measured numerically. A line with a length of 100 mm has the words "no pain" at one end and "the most unbearable pain" on the other. The patient indicates his/her pain by choosing the most appropriate place on the line. Then, the level of pain experienced by the patient is determined by using a scale with scores between 0-10. According to this scoring system, less than 3 points indicate mild pain, 3-6 points indicate moderate pain, and more than 6 points indicate severe pain.
day 1
Blood glucose before insulin injection
Time Frame: day 1
Before the administration blood glucose (mg/dl) of all patients (topical lavender oil, placebo, and control groups) were measured. Blood glucose measurement is done with a blood glucose meter (glucometer) and a measuring stick (strip). Fasting blood glucose 70-125 mg / dl was considered normal.
day 1
Oxygen Saturation (SPO2) before insulin injection
Time Frame: day 1
Before the administration oxygen saturation level (SPO2)(%) of all patients (topical lavender oil, placebo, and control groups) were measured. The researcher measured the oxygen saturation in subcutaneous arterial blood with a "Pulse oximeter" device that is reliable, easy to use, does not require calibration and does not cause pain to the patient in its application. Normal value of oxygen saturation (SpO2) (%) was accepted as 96-98%. After placing a probe in the periphery (on the patient's finger) by the investigator, the signal received from the periphery and the value on the image screen (monitor) where the pulse wave sample was projected was recorded as oxygen saturation.
day 1
Systolic and Diastolic Blood Pressure before insulin injection
Time Frame: day 1
Before the administration blood pressure (mm/Hg) of all patients (topical lavender oil, placebo, and control groups) were measured. Blood Pressure Measurement was performed using a conventional cuffed sphygmomanometer that can measure systolic and diastolic blood pressure, whose reliability was approved according to international standards and calibrated by the company in technical laboratories for certain periods. The cuff of the sphygmomanometer will be inflated to 20 mm / Hg above the systolic pressure by tying it to cover 2/3 of the arm, and the measurement will be carried out by the researcher.
day 1
Pulse rate before insulin injection
Time Frame: day 1
Before the administration pulse rate (min) of all patients (topical lavender oil, placebo, and control groups) were measured. The pulse was obtained by the investigator palpating the superficial arteries (by touching them with the hand) and counting the beats felt for one minute. 60 to 100 beats per minute was considered normal for an adult.
day 1
Respiration rate before insulin injection
Time Frame: day 1
Before the administration Respiration rate (min) of all patients (topical lavender oil, placebo, and control groups) were measured. Respiration rate was measured by the number of diaphragm movements per minute. For an adult at rest, 12 to 20 per minute was considered normal for respiratory rate.
day 1
Blood glucose after insulin injection
Time Frame: day 1
After the administration blood glucose (mg/dl) of all patients (topical lavender oil, placebo, and control groups) were measured. Blood glucose measurement is done with a blood glucose meter (glucometer) and a measuring stick (strip). Fasting blood glucose 140-199 mg / dl was considered normal.
day 1
Oxygen Saturation (SPO2) after insulin injection
Time Frame: day 1
After the administration oxygen saturation level (SPO2)(%) of all patients (topical lavender oil, placebo, and control groups) were measured. The researcher measured the oxygen saturation in subcutaneous arterial blood with a "Pulse oximeter" device that is reliable, easy to use, does not require calibration and does not cause pain to the patient in its application. Normal value of oxygen saturation (SpO2) (%) was accepted as 96-98%. After placing a probe in the periphery (on the patient's finger) by the investigator, the signal received from the periphery and the value on the image screen (monitor) where the pulse wave sample was projected was recorded as oxygen saturation.
day 1
Systolic and Diastolic Blood Pressure after insulin injection
Time Frame: day 1
After the administration blood pressure (mm/Hg) of all patients (topical lavender oil, placebo, and control groups) were measured. Blood Pressure Measurement was performed using a conventional cuffed sphygmomanometer that can measure systolic and diastolic blood pressure, whose reliability was approved according to international standards and calibrated by the company in technical laboratories for certain periods. The cuff of the sphygmomanometer will be inflated to 20 mm / Hg above the systolic pressure by tying it to cover 2/3 of the arm, and the measurement will be carried out by the researcher.
day 1
Pulse rate after insulin injection
Time Frame: day 1
After the administration pulse rate (min) of all patients (topical lavender oil, placebo, and control groups) were measured. The pulse was obtained by the investigator palpating the superficial arteries (by touching them with the hand) and counting the beats felt for one minute. 60 to 100 beats per minute was considered normal for an adult.
day 1
Respiration rate after insulin injection
Time Frame: day 1
After the administration Respiration rate (min) of all patients (topical lavender oil, placebo, and control groups) were measured. Respiration rate was measured by the number of diaphragm movements per minute. For an adult at rest, 12 to 20 per minute was considered normal for respiratory rate.
day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 1, 2020

Primary Completion (ACTUAL)

May 31, 2020

Study Completion (ACTUAL)

July 31, 2020

Study Registration Dates

First Submitted

November 26, 2020

First Submitted That Met QC Criteria

February 22, 2021

First Posted (ACTUAL)

February 23, 2021

Study Record Updates

Last Update Posted (ACTUAL)

February 23, 2021

Last Update Submitted That Met QC Criteria

February 22, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • RCT1004201704062014

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

I'll decide later

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Topically Administered Lavender Aromatherapy

Subscribe